Access to Evidence-Based Statins in Low-Cost Generic Drug Programs.
From the Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA (C.A.J., K.C.); Institute for Clinical Evaluative Sciences, ON, Toronto, Canada (C.A.J.); Pharmacy Department, Veterans Affairs Greater Los Angeles Healthcare System, CA (C.A.J.); Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, ON, Canada (C.A.J.); Pharmacy Department, University Health Network, Toronto, Canada (C.A.J.); Department of Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven CT (H.M.K.); Department of Health Policy and Management, New Haven, CT (H.M.K.); and Robert Wood Johnson Foundation Clinical Scholars Program, New Haven, CT (H.M.K.). cjackevicius@westernu.edu.
Cynthia A
CA
Jackevicius
From the Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA (C.A.J., K.C.); Institute for Clinical Evaluative Sciences, ON, Toronto, Canada (C.A.J.); Pharmacy Department, Veterans Affairs Greater Los Angeles Healthcare System, CA (C.A.J.); Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, ON, Canada (C.A.J.); Pharmacy Department, University Health Network, Toronto, Canada (C.A.J.); Department of Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven CT (H.M.K.); Department of Health Policy and Management, New Haven, CT (H.M.K.); and Robert Wood Johnson Foundation Clinical Scholars Program, New Haven, CT (H.M.K.).
Katie
K
Choi
From the Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA (C.A.J., K.C.); Institute for Clinical Evaluative Sciences, ON, Toronto, Canada (C.A.J.); Pharmacy Department, Veterans Affairs Greater Los Angeles Healthcare System, CA (C.A.J.); Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, ON, Canada (C.A.J.); Pharmacy Department, University Health Network, Toronto, Canada (C.A.J.); Department of Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven CT (H.M.K.); Department of Health Policy and Management, New Haven, CT (H.M.K.); and Robert Wood Johnson Foundation Clinical Scholars Program, New Haven, CT (H.M.K.).
Harlan M
HM
Krumholz
D016527:Drug Costs; D016568:Drugs, Generic; D019317:Evidence-Based Medicine; D006297:Health Services Accessibility; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D055553:Prescription Drugs
D016568:Drugs, Generic; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D055553:Prescription Drugs
3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors; drug costs; evidence-based medicine; generic drugs; prescription drugs